Edwards Lifesciences price target raised to $90-$91 from $82-$83 at Wells Fargo Wells Fargo increased its price target on Edwards after a federal court granted a preliminary injunction limiting the sale of a competing product, Medtronic's (MDT) CoreValve. The firm said the injunction was a "major surprise," and estimates that the injunction could increase Edwards EPS by 15c in 2014 and 34c in 2015. Wells keeps an Outperform rating on the stock.
Senate Health, Education, Labor & Pensions Committee to hold a hearing The Committee holds a hearing entitled, "Continuing America’s Leadership: Advancing Research and Development for Patients" with Chairman & CEO Mussallem of Edwards Lifesciences on March 24 at 10 am. Webcast Link